(Q34458673)

2 August 2017

1 reference

title

Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer (English)

1 reference

2 August 2017

1 reference

G L Plosker

1

1 reference

2 August 2017

M Hurst

series ordinal

2

1 reference

2 August 2017

publication date

1 January 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

19

1 reference

2 August 2017

issue

11

1 reference

2 August 2017

page(s)

1111-1134

1 reference

Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer

2 August 2017

cites work

1 reference

12 December 2020

A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

1 reference

12 December 2020

Rationale for non-platinum chemotherapy in advanced NSCLC.

1 reference

12 December 2020

A phase I/II study of paclitaxel (TAXOL) and concurrent radiotherapy in advanced nonsmall cell lung cancer

1 reference

12 December 2020

Effectiveness and hematotoxicity of paclitaxel monotherapy in patients with advanced non-small cell bronchial carcinoma (NSCLC)

1 reference

12 December 2020

Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG)

1 reference

12 December 2020

Review of paclitaxel/carboplatin in advanced non-small cell lung cancer.

1 reference

12 December 2020

Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response.

1 reference

12 December 2020

Induction chemotherapy before surgery for early-stage lung cancer: A novel approach

1 reference

12 December 2020

Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer

1 reference

12 December 2020

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

1 reference

12 December 2020

Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

1 reference

12 December 2020

Taxol hypersensitivity: rapid retreatment is safe and cost effective

1 reference

12 December 2020

Costs of care associated with non-small-cell lung cancer in a commercially insured cohort

1 reference

12 December 2020

Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers

1 reference

12 December 2020

Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer.

1 reference

12 December 2020

Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer

1 reference

12 December 2020

The Royal College of Radiologists Clinical Oncology Information Network. Guidelines on the non-surgical management of lung cancer

1 reference

12 December 2020

Some guidelines on the use of cost effectiveness league tables

1 reference

12 December 2020

Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer

1 reference

12 December 2020

Economic issues in lung cancer: a review

1 reference

12 December 2020

Phase II study of 3-hour infusion of paclitaxel in patients with previously untreated stage III and IV non-small cell lung cancer. West Japan Lung Cancer Group

1 reference

12 December 2020

Clinical pharmacology of carboplatin administered in combination with paclitaxel

1 reference

12 December 2020

Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study

1 reference

12 December 2020

Gemcitabine and paclitaxel combinations in non-small cell lung cancer

1 reference

12 December 2020

Preliminary analysis of a phase II study of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer

1 reference

12 December 2020

Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.

1 reference

12 December 2020

Does knowledge guide practice? Another look at the management of non-small-cell lung cancer

1 reference

12 December 2020

Single-agent paclitaxel in advanced non-small cell lung cancer: single-center phase II study using a 3-hour administration schedule.

1 reference

12 December 2020

Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer

1 reference

12 December 2020

Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology

1 reference

12 December 2020

Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial.

1 reference

12 December 2020

1 reference

12 December 2020

Paclitaxel and docetaxel combinations in non-small cell lung cancer

1 reference

12 December 2020

Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer.

1 reference

12 December 2020

The current role and future prospects of paclitaxel in the treatment of small cell lung cancer

1 reference

12 December 2020

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations

1 reference

12 December 2020

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

12 December 2020

The taxoids: paclitaxel and docetaxel

1 reference

12 December 2020

Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy

1 reference

12 December 2020

A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

1 reference

12 December 2020

Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.

1 reference

12 December 2020

The emerging world role of irinotecan in lung cancer.

1 reference

12 December 2020

Paclitaxel in advanced non-small cell lung cancer : an alternative high-dose weekly schedule

1 reference

12 December 2020

A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer

1 reference

12 December 2020

Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer

1 reference

12 December 2020

The cost-effectiveness of paclitaxel (Taxol) + cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer: a multicountry analysis.

1 reference

12 December 2020

Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer

1 reference

12 December 2020

Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.

1 reference

12 December 2020

Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics.

1 reference

12 December 2020

Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: a preliminary report on an active regimen

1 reference

12 December 2020

Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial

1 reference

12 December 2020

Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer

1 reference

12 December 2020

10.2165/00019053-200119110-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

1044347907

0 references

1 reference